Analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.
OpGen Stock Down 13.2 %
Shares of NASDAQ:OPGN opened at $1.65 on Thursday. The company has a 50 day moving average of $1.92 and a 200 day moving average of $3.01. OpGen has a 12 month low of $1.61 and a 12 month high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last released its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The business had revenue of $0.03 million for the quarter.
Institutional Investors Weigh In On OpGen
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- How to Invest in Biotech Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Trending Stocks? Trending Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Business Services Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.